Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Targeting DNA Repair in Ovarian Cancer Treatment Resistance.

Clinical oncology (Royal College of Radiologists (Great Britain)) - 1 Aug 2020

Wong-Brown M W, van der Westhuizen A, Bowden N A

Abstract excerpt

Most patients with advanced high-grade serous ovarian cancer (HGSOC) develop recurrent disease within 3 years and succumb to the disease within 5 years. Standard treatment for HGSOC is cytoreductive surgery followed by a combination of platinum (carboplatin or cisplatin) and taxol (paclitaxel) chemotherapies. Although initial recurrences are usually platinum-sensitive, patients eventually develop resistance to...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Antineoplastic Agents
Share to DNA Damage
Share to DNA Methylation

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to DNA Repair

Share to DNA Repair Enzymes

Share to Drug Resistance, Neoplasm

Share to Mutation

Share to Ovarian Neoplasms

Source

Identifiers

PMID: 32253106
DOI: 10.1016/j.clon.2020.03.005

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 6 Sept 2026. Manifest publication-graph-cohort-2026-09-06.1.

Source receipt: pubmed, retrieved 6 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Targeting DNA Repair in Ovarian Cancer Treatment Resistance.PMID 32253106Read ↗

Platinum Resistance in Ovarian Cancer: Role of DNA RepairSemantic proximity Read ↗

Reversing Platinum Resistance in High-Grade Serous Ovarian Carcinoma: Targeting BRCA and the Homologous Recombination SystemSemantic proximity Read ↗

Ovarian Cancer—Insights into Platinum Resistance and Overcoming ItSemantic proximity Read ↗

Tailoring Ovarian Cancer Treatment: Implications of BRCA1/2 MutationsSemantic proximity Read ↗

Ovarian cancer recurrence: “is the definition of platinum resistance modified by PARP inhibitors and other intervening treatments?”Semantic proximity Read ↗

DNA damage repair in ovarian cancer: unlocking the heterogeneitySemantic proximity Read ↗

Lessons learned from understanding chemotherapy resistance in epithelial tubo-ovarian carcinoma from BRCA1and BRCA2mutation carriers.Semantic proximity Read ↗

Platinum resistance induces diverse evolutionary trajectories in high grade serous ovarian cancerSemantic proximity Read ↗

DNA damaging agents in ovarian cancerSemantic proximity Read ↗

Unveiling drug resistance pathways in high-grade serous ovarian cancer(HGSOC): recent advances and future perspectivesSemantic proximity Read ↗

Ovarian cancer.Semantic proximity Read ↗

DNA repair and the contribution to chemotherapy resistanceSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.